DNA修復藥物市場－全球產業規模、佔有率、趨勢、機會和預測：按藥物類型、應用、分銷管道、地區和競爭格局分類，2021-2031年

全球 DNA 修復藥物市場預計將經歷顯著成長，市場規模預計將從 2025 年的 79.1 億美元成長到 2031 年的 163.9 億美元，複合年成長率高達 12.91%。

這些特效療法旨在靶向並抑制DNA損害反應路徑中的蛋白質，從而誘導具有固有修復缺陷的癌細胞產生合成致死效應。推動這一市場擴張的關鍵因素包括全球癌症發生率的上升以及精準腫瘤學研發的深入發展。根據美國製藥商協會（PhRMA）預測，到2025年，將有1120種癌症療法和疫苗正在研發中，這顯示製藥業正致力於解決複雜的腫瘤突變問題。這也持續推動對新型DNA修復機制的需求。然而，長期接受治療的患者出現抗藥性，為市場帶來了重大挑戰。這不僅降低了臨床療效，也限制了這些先進治療方法的適用人群。

市場促進因素

DNA修復功能缺陷導致的癌症發生率不斷上升，是推動全球市場擴張的主要動力。隨著攜帶特定基因脆弱性（例如BRCA突變）的腫瘤盛行率持續成長，迫切需要能夠透過合成致死效應來靶向這些缺陷的治療方法。基因組分析的廣泛應用進一步加劇了這種需求，因為基因組分析能夠幫助臨床醫生精準識別最能從DNA損害反應（DDR）抑制劑中獲益的患者。根據美國癌症協會發布的《2025年癌症事實與數據》，預計到2025年1月，美國將新增2,041,910例癌症病例，這凸顯了開發有效、精準的治療性介入以應對日益成長的疾病負擔的迫切需求。同時，對新型DNA修復通路研發投入的大幅成長正積極重塑競爭格局，並加速藥物研發管線的開發。為了克服抗藥性機制，製藥公司正大力投資於識別和檢驗新一代標靶（例如ATR和WEE1激酶），以超越傳統的PARP抑制劑。例如，Astra Zeneca在2025年2月宣布，其研發總投資額達135.8億美元，年增25%，以支持其正在進行的腫瘤和生物製藥產品組合。這項資金投入也推動了高價值的商業性合作。例如，在同一時期，Astra Zeneca從其DNA修復藥物Lympalza的銷售里程碑付款中累計了6億美元的合作收入。

市場挑戰

抗藥性的出現對全球DNA修復藥物市場的成長構成了重大障礙。儘管這些治療方法旨在靶向DNA損害反應路徑中的特定脆弱點，但癌細胞經常發展出適應性機制，使其能夠恢復修復能力，甚至完全繞過被抑制的路徑。這種生物適應性顯著限制了藥物的長期療效，並且常常導致藥物在一段時間的治療後失效。因此，由於符合長期治療條件的患者數量減少，以及通常因藥物敏感性降低而產生持續收入的治療持續時間顯著縮短，這些藥物的商業潛力受到限制。持續高商業性（主要由治療失敗和疾病進展引起）凸顯了這項挑戰的嚴峻性。根據美國癌症協會估計，到2025年，美國預計將有618,120人死於癌症。這項統計數據表明，現有治療方法在克服腫瘤適應性生物學方面有顯著局限性。現有的 DNA 修復抑制劑無法阻止大多數患者病情惡化至致命程度，這一事實直接阻礙了市場成長，因為這些治療方法無法充分發揮其作為治癒性長期解決方案的潛力。

市場趨勢

一個值得關注的趨勢是將DNA修復抑制劑和免疫查核點抑制劑進行策略性整合，這代表著一種向協同聯合治療的轉變，旨在增強治療的永續性。 DNADNA損害反應（DDR）藥物，例如PARP抑制劑，透過誘導雙鏈來增加腫瘤突變負荷，刺激新抗原釋放，使癌細胞對免疫療法更加敏感。這種生物協同作用使研發人員能夠增強查核點抑制劑在通常缺乏免疫浸潤的「冷」腫瘤中的療效，為擴大這兩類藥物的目標市場創造了充滿希望的機會。這種方法的商業性可行性得益於這些新療法中使用的基礎查核點抑制劑的持續銷售成長。例如，默克公司報告稱，截至2024年10月，Keytruda的全球銷售額成長了17%，達到74億美元，這主要得益於其在聯合治療中的應用增加。這凸顯了業界致力於探索免疫療法和DDR藥物聯合療法的決心。同時，人工智慧（AI）在DNA損傷修復（DDR）藥物研發的應用正在革新合成致死標靶的識別和先導化合物的最佳化。機器學習演算法正被擴大用於分析海量基因組資料集，預測哪些新型DNA修復依賴性可在特定腫瘤亞型中得到利用，其速度和準確性均優於傳統的高通量篩檢。這項技術的整合大幅縮短了將有前景的候選化合物推進臨床開發所需的時間和成本，吸引了大量投資湧入人工智慧驅動的生物技術企業。例如，Xaira Therapeutics已獲得10億美元的投資承諾，用於2024年4月前建立端到端的藥物研發平台。這顯示業界對利用計算方法加速DNA修復等複雜治療藥物研發管線的進展越來越有信心。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球DNA修復藥物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 藥物類型（烷化劑、PARP抑制劑、拓樸異構酶抑制劑、其他）
  • 依應用領域（神經退化性疾病、腫瘤、心血管疾病、中風）
  • 分銷通路（零售藥局、醫院藥局、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美DNA修復藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲DNA修復藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區DNA修復藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲DNA修復藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲DNA修復藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球DNA修復藥物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• Abbvie Inc.
• Pfizer Inc.
• Astrazeneca plc
• Sanofi SA
• Bayer AG
• Gilead Sciences Inc.
• Merck & Co. Inc.
• Novartis AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global DNA Repair Drugs Market is projected for significant growth, with its valuation expected to rise from USD 7.91 Billion in 2025 to USD 16.39 Billion by 2031, reflecting a robust 12.91% Compound Annual Growth Rate. These specialized therapeutic agents are designed to target and inhibit proteins within the DNA damage response pathway, aiming to induce synthetic lethality in cancer cells that possess inherent repair defects. The primary drivers underpinning this market's expansion include the escalating global incidence of oncological diseases and an intensive research focus on precision oncology pipelines. The industry's commitment to addressing complex tumor variations is evident, with 1,120 new medicines and vaccines for cancer in development in 2025, according to the Pharmaceutical Research and Manufacturers of America, thereby fueling a continuous demand for novel DNA repair mechanisms. However, the market faces a significant impediment due to the emergence of drug resistance in patients undergoing prolonged treatment, which diminishes clinical efficacy and restricts the eligible patient population for these advanced therapies.

Market Driver

The increasing incidence of cancers characterized by DNA repair deficiencies serves as a principal catalyst for the global market's expansion. As the prevalence of tumors harboring specific genetic vulnerabilities, such as BRCA mutations, continues to grow, there is an urgent need for targeted therapeutics capable of exploiting these defects through synthetic lethality. This demand is further amplified by the widespread adoption of genomic profiling, which enables clinicians to precisely identify patients who stand to benefit most from DNA damage response (DDR) inhibitors. According to the American Cancer Society's 'Cancer Facts & Figures 2025', an estimated 2,041,910 new cancer cases were projected to be diagnosed in the United States in January 2025, underscoring the critical requirement for effective precision oncology interventions to address this rising disease burden. Concurrently, a substantial surge in R&D investments toward novel DNA repair pathways is actively reshaping the competitive landscape and accelerating pipeline development. Pharmaceutical companies are allocating significant capital to identify and validate next-generation targets beyond standard PARP inhibition, such including ATR and WEE1 kinases, in an effort to overcome resistance mechanisms. For instance, AstraZeneca reported a total research and development investment of $13.58 billion in February 2025, representing a 25% year-on-year increase to support its advancing oncology and biopharmaceutical portfolios. This financial commitment also facilitates high-value commercial partnerships, as evidenced by AstraZeneca recording $600 million in collaboration revenue specifically derived from sales-related milestones for the DNA repair drug Lynparza in the same period.

Market Challenge

The emergence of drug resistance presents a substantial barrier to the growth of the Global DNA Repair Drugs Market. While these therapies are engineered to target specific vulnerabilities within the DNA damage response pathway, tumor cells frequently develop adaptive mechanisms, enabling them to restore their repair capacity or entirely bypass the inhibited pathways. This biological adaptation severely limits the long-term efficacy of the drugs, often rendering them ineffective after a distinct period of treatment. Consequently, the commercial potential of these agents is restricted, as the patient population eligible for prolonged therapy diminishes, and the treatment window-which typically generates recurring revenue-is significantly shortened by the onset of insensitivity to the medication. The persistence of high mortality rates, largely driven by treatment failure and disease progression, underscores the magnitude of this challenge. According to the American Cancer Society, an estimated 618,120 cancer deaths were projected in the United States in 2025. This statistic highlights the critical limitation of current interventions to overcome adaptive tumor biology. The inability of existing DNA repair inhibitors to prevent fatal progression in a large segment of the patient population directly hampers market growth by preventing these therapies from achieving their full potential as curative, long-term solutions.

Market Trends

A prominent trend involves the strategic integration of DNA repair inhibitors with immune checkpoint blockade, representing a shift toward synergistic combination therapies designed to enhance treatment durability. DNA damage response (DDR) agents, such as PARP inhibitors, induce double-strand breaks that increase the tumor mutational burden and stimulate neoantigen release, thereby rendering cancer cells more susceptible to immunotherapy. This biological cooperation allows developers to potentiate the efficacy of checkpoint inhibitors in "cold" tumors that typically lack immune infiltration, creating a lucrative opportunity to expand the addressable market for both drug classes. The commercial viability of this approach is evidenced by the sustained revenue growth of foundational checkpoint inhibitors utilized in these novel regimens; Merck, for instance, reported that worldwide sales of Keytruda grew 17% to $7.4 billion by October 2024, a performance driven by its expanded use in combination settings, which validates the industry's pursuit of pairing immunotherapies with DDR agents. Concurrently, the application of artificial intelligence (AI) in DDR drug discovery is revolutionizing the identification of synthetic lethality targets and the optimization of lead compounds. Machine learning algorithms are increasingly utilized to analyze vast genomic datasets, predicting which novel DNA repair dependencies can be exploited in specific tumor subtypes with greater speed and accuracy than traditional high-throughput screening. This technological integration significantly reduces the time and capital required to bring viable candidates into clinical development, attracting substantial investment into AI-driven biotech initiatives. For example, Xaira Therapeutics secured $1 billion in committed capital by April 2024 to build an end-to-end platform for drug creation, signaling massive industry confidence in using computational methods to accelerate the advancement of complex therapeutic pipelines like those in DNA repair.

Key Market Players

• GlaxoSmithKline plc
• F. Hoffmann-La Roche Ltd.
• Abbvie Inc.
• Pfizer Inc.
• Astrazeneca plc
• Sanofi S.A.
• Bayer AG
• Gilead Sciences Inc.
• Merck & Co. Inc.
• Novartis AG

Report Scope

In this report, the Global DNA Repair Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

DNA Repair Drugs Market, By Drug Type

• Alkylating Agents
• PARP Inhibitors
• Topoisomerase Inhibitors
• Other

DNA Repair Drugs Market, By Application

• Neurodegenerative Diseases
• Oncological
• Cardiovascular Diseases
• Stroke

DNA Repair Drugs Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Others

DNA Repair Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global DNA Repair Drugs Market.

Available Customizations:

Global DNA Repair Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global DNA Repair Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Alkylating Agents, PARP Inhibitors, Topoisomerase Inhibitors, Other)
  • 5.2.2. By Application (Neurodegenerative Diseases, Oncological, Cardiovascular Diseases, Stroke)
  • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America DNA Repair Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States DNA Repair Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada DNA Repair Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico DNA Repair Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe DNA Repair Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany DNA Repair Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France DNA Repair Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom DNA Repair Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy DNA Repair Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain DNA Repair Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific DNA Repair Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China DNA Repair Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India DNA Repair Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan DNA Repair Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea DNA Repair Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia DNA Repair Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa DNA Repair Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia DNA Repair Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE DNA Repair Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa DNA Repair Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America DNA Repair Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil DNA Repair Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia DNA Repair Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina DNA Repair Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global DNA Repair Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GlaxoSmithKline plc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Abbvie Inc.
• 15.4. Pfizer Inc.
• 15.5. Astrazeneca plc
• 15.6. Sanofi S.A.
• 15.7. Bayer AG
• 15.8. Gilead Sciences Inc.
• 15.9. Merck & Co. Inc.
• 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer